Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027957 | 0.93 | F2 (0.48) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7702634 | 0.83 | F2 (0.47) | F2PRSS1PRSS2PRSS3 | |
| Acetic Acid SCHEMBL6078151 | 0.80 | F2 (0.58) | F2PRSS1 | |
| SCHEMBL14423545 | 0.77 | F2 (0.46) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14423560 | 0.76 | F2 (0.38) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14423556 | 0.75 | F2 (0.41) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7342783 | 0.74 | F2 (0.48) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5117233 | 0.72 | F2 (0.58) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6028255 | 0.71 | OPRK1 (0.45) | — | |
| SCHEMBL7341001 | 0.71 | F2 (0.56) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706396-A1 | N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F.HOFFMANN-LA ROCHE AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-7056932-B2 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2005058868-A1 | N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMANN-LA ROCHE INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | F12, TFPI, F11 | F2 7/4885PRSS1 311/4885PRSS2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.